CA2300097C - Liver function test - Google Patents
Liver function test Download PDFInfo
- Publication number
- CA2300097C CA2300097C CA002300097A CA2300097A CA2300097C CA 2300097 C CA2300097 C CA 2300097C CA 002300097 A CA002300097 A CA 002300097A CA 2300097 A CA2300097 A CA 2300097A CA 2300097 C CA2300097 C CA 2300097C
- Authority
- CA
- Canada
- Prior art keywords
- acid derivative
- bile acid
- patient
- plasma
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000007449 liver function test Methods 0.000 title description 6
- 210000002381 plasma Anatomy 0.000 claims abstract description 52
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 44
- 230000008030 elimination Effects 0.000 claims abstract description 31
- 238000003379 elimination reaction Methods 0.000 claims abstract description 31
- 230000003908 liver function Effects 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 19
- 210000004185 liver Anatomy 0.000 claims abstract description 14
- 238000012545 processing Methods 0.000 claims abstract description 13
- 238000005259 measurement Methods 0.000 claims abstract description 10
- ZUJFMZPBQQCXQR-UHFFFAOYSA-N 5-[[5-carboxy-5-[4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoylamino]pentyl]carbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid Chemical compound OC1CC2CC(O)CCC2(C)C(CC(O)C23C)C1C3CCC2C(C)CCC(=O)NC(C(O)=O)CCCCNC(=S)NC1=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C(C(O)=O)=C1 ZUJFMZPBQQCXQR-UHFFFAOYSA-N 0.000 claims description 37
- 239000003613 bile acid Substances 0.000 claims description 14
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 7
- 150000003431 steroids Chemical group 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
- 239000004380 Cholic acid Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 5
- 229960002471 cholic acid Drugs 0.000 claims description 5
- 235000019416 cholic acid Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 3
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims description 2
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 claims description 2
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 claims description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- IKHFJPZQZVMLRH-RNFRBKRXSA-N 2-[[[(3r,5r)-3,6-diamino-5-hydroxyhexanoyl]amino]-methylamino]acetic acid Chemical compound OC(=O)CN(C)NC(=O)C[C@H](N)C[C@@H](O)CN IKHFJPZQZVMLRH-RNFRBKRXSA-N 0.000 claims description 2
- RPKLZQLYODPWTM-NIRKWIOJSA-N 5alpha-cholanic acid Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RPKLZQLYODPWTM-NIRKWIOJSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- 239000005700 Putrescine Substances 0.000 claims description 2
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 2
- 229960001570 ademetionine Drugs 0.000 claims description 2
- BHQCQFFYRZLCQQ-PGHAKIONSA-N allocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-PGHAKIONSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 2
- 229940099500 cystamine Drugs 0.000 claims description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 2
- 125000001288 lysyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003151 mercaptamine Drugs 0.000 claims description 2
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims description 2
- IKHFJPZQZVMLRH-UHFFFAOYSA-N negamycin Natural products OC(=O)CN(C)NC(=O)CC(N)CC(O)CN IKHFJPZQZVMLRH-UHFFFAOYSA-N 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 2
- 229960001661 ursodiol Drugs 0.000 claims description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003858 bile acid conjugate Substances 0.000 description 9
- 108010007979 Glycocholic Acid Proteins 0.000 description 7
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 208000007788 Acute Liver Failure Diseases 0.000 description 3
- 206010000804 Acute hepatic failure Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013534 fluorescein angiography Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 101710081513 Alkaline phosphatase 3 Proteins 0.000 description 1
- 101710203253 Aspartate aminotransferase 2 Proteins 0.000 description 1
- 102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/728—Bilirubin; including biliverdin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/146666—Bile pigment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9716962.7 | 1997-08-12 | ||
| GBGB9716962.7A GB9716962D0 (en) | 1997-08-12 | 1997-08-12 | Liver function test |
| PCT/GB1998/002322 WO1999007325A1 (en) | 1997-08-12 | 1998-08-03 | Liver function test |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2300097A1 CA2300097A1 (en) | 1999-02-18 |
| CA2300097C true CA2300097C (en) | 2004-10-12 |
Family
ID=10817313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002300097A Expired - Fee Related CA2300097C (en) | 1997-08-12 | 1998-08-03 | Liver function test |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6030841A (ja) |
| EP (1) | EP1003458B1 (ja) |
| JP (1) | JP3477616B2 (ja) |
| KR (1) | KR100444564B1 (ja) |
| CN (2) | CN1991367A (ja) |
| AT (1) | ATE226415T1 (ja) |
| AU (1) | AU732900B2 (ja) |
| CA (1) | CA2300097C (ja) |
| DE (1) | DE69808930T2 (ja) |
| DK (1) | DK1003458T3 (ja) |
| ES (1) | ES2183399T3 (ja) |
| GB (1) | GB9716962D0 (ja) |
| HK (1) | HK1024413A1 (ja) |
| PT (1) | PT1003458E (ja) |
| WO (1) | WO1999007325A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001297A1 (de) * | 1998-07-01 | 2000-01-13 | Andreas Hoeft | Bestimmung der leberfunktion anhand einer plasmaverschwinderate |
| SE521014C2 (sv) | 1999-02-04 | 2003-09-23 | Prostalund Operations Ab | Anordning för värmebehandling av prostata |
| SE521275C2 (sv) | 1999-05-07 | 2003-10-14 | Prostalund Operations Ab | Anordning vid värmebehandling av kroppsvävnad |
| GB0017822D0 (en) * | 2000-07-21 | 2000-09-06 | Norgine Europe Bv | Pharmaceutically active compound |
| US6868290B2 (en) | 2001-11-05 | 2005-03-15 | Prostalund Operations Ab | Thermotherapy catheter and method of prostate thermotherapy with improved guide and heat confinement |
| SK2292004A3 (en) * | 2001-11-26 | 2004-09-08 | Cortex Pharma Inc | Carbonyl benzoxazine compounds for enhancement of glutamatergic synaptic responses |
| CN100502763C (zh) * | 2002-12-09 | 2009-06-24 | 味之素株式会社 | 生物体状态信息处理装置和其方法、以及生物体状态信息管理系统 |
| GB0808777D0 (en) | 2008-05-15 | 2008-06-18 | Norgine Bv | Prognostic method |
| GB2467902A (en) | 2009-02-12 | 2010-08-18 | Norgine Bv | Preparation of Cholyl-L-lysine from N-E-CBZ-cholyl-L-lysine |
| JP2010261871A (ja) * | 2009-05-08 | 2010-11-18 | Geno Membrane:Kk | 標識化胆汁酸 |
| CN102488525B (zh) * | 2011-12-14 | 2014-04-16 | 吉林大学 | 一种去血氧波动干扰的肝储备功能检测装置 |
| US20150212068A1 (en) * | 2012-08-20 | 2015-07-30 | Novassay Sa | Cholyl-L-Lysyl-Fluorescein Assay |
| CN104688234A (zh) * | 2015-03-17 | 2015-06-10 | 吉林大学 | 一种icg色素浓度谱的无创、抗扰动检测方法 |
| KR101882485B1 (ko) | 2016-06-30 | 2018-07-27 | 강경찬 | 체내 간기능효소 및 지질 함유량 측정방법 |
| CN106749473B (zh) * | 2017-01-13 | 2018-08-17 | 常德云港生物科技有限公司 | 一种从鸭胆汁中提取鹅去氧胆酸和别胆酸的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264514A (en) * | 1977-11-14 | 1981-04-28 | Abbott Laboratories | Method and reagents for measuring the level of conjugated bile acids |
| US4848349A (en) * | 1987-04-29 | 1989-07-18 | Sherman Igor A | Substance and method for measuring hepatic blood flow |
| JPH0657216B2 (ja) * | 1988-09-14 | 1994-08-03 | 住友電気工業株式会社 | 肝機能検査装置 |
| GB9517043D0 (en) * | 1995-08-19 | 1995-10-25 | Univ Birmingham | The use of bile acid derivatives |
-
1997
- 1997-08-12 GB GBGB9716962.7A patent/GB9716962D0/en active Pending
-
1998
- 1998-02-27 US US09/032,325 patent/US6030841A/en not_active Expired - Lifetime
- 1998-08-03 AU AU85530/98A patent/AU732900B2/en not_active Ceased
- 1998-08-03 PT PT98936568T patent/PT1003458E/pt unknown
- 1998-08-03 DK DK98936568T patent/DK1003458T3/da active
- 1998-08-03 DE DE69808930T patent/DE69808930T2/de not_active Expired - Lifetime
- 1998-08-03 WO PCT/GB1998/002322 patent/WO1999007325A1/en active IP Right Grant
- 1998-08-03 CN CNA2006101693366A patent/CN1991367A/zh active Pending
- 1998-08-03 KR KR10-2000-7001407A patent/KR100444564B1/ko not_active IP Right Cessation
- 1998-08-03 CN CN98810086A patent/CN1275060A/zh active Pending
- 1998-08-03 AT AT98936568T patent/ATE226415T1/de active
- 1998-08-03 ES ES98936568T patent/ES2183399T3/es not_active Expired - Lifetime
- 1998-08-03 CA CA002300097A patent/CA2300097C/en not_active Expired - Fee Related
- 1998-08-03 EP EP98936568A patent/EP1003458B1/en not_active Expired - Lifetime
- 1998-08-03 JP JP2000506922A patent/JP3477616B2/ja not_active Expired - Fee Related
-
2000
- 2000-06-22 HK HK00103782A patent/HK1024413A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010022806A (ko) | 2001-03-26 |
| EP1003458B1 (en) | 2002-10-23 |
| KR100444564B1 (ko) | 2004-08-16 |
| ATE226415T1 (de) | 2002-11-15 |
| CN1275060A (zh) | 2000-11-29 |
| WO1999007325A8 (en) | 1999-03-25 |
| CA2300097A1 (en) | 1999-02-18 |
| US6030841A (en) | 2000-02-29 |
| DK1003458T3 (da) | 2002-11-18 |
| AU8553098A (en) | 1999-03-01 |
| AU732900B2 (en) | 2001-05-03 |
| EP1003458A2 (en) | 2000-05-31 |
| DE69808930D1 (de) | 2002-11-28 |
| CN1991367A (zh) | 2007-07-04 |
| HK1024413A1 (en) | 2000-10-13 |
| ES2183399T3 (es) | 2003-03-16 |
| PT1003458E (pt) | 2003-01-31 |
| JP3477616B2 (ja) | 2003-12-10 |
| WO1999007325A1 (en) | 1999-02-18 |
| DE69808930T2 (de) | 2003-08-07 |
| JP2001513584A (ja) | 2001-09-04 |
| GB9716962D0 (en) | 1997-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2300097C (en) | Liver function test | |
| Houglum et al. | Excess iron induces hepatic oxidative stress and transforming growth factor β1 in genetic hemochromatosis | |
| Ceryak et al. | Comparative binding of bile acids to serum lipoproteins and albumin | |
| Fleishaker et al. | Phenytoin causes a rapid increase in 6β‐hydroxycortisol urinary excretion in humans—a putative measure of CYP3A induction | |
| Kydd et al. | Precipitable iodine of serum (SPI) in disorders of the liver | |
| Setchell et al. | On the homogeneity of stools with respect to bile acid composition and normal day-to-day variations: a detailed qualitative and quantitative study using capillary column gas chromatography-mass spectrometry | |
| Klaassen et al. | Biliary excretion of xenobiotics | |
| Schalm et al. | Radioimmunoassay of bile acids: development, validation, and preliminary application of an assay for conjugates of chenodeoxycholic acid | |
| Berk et al. | Hyperbilirubinemia and cholestasis | |
| Jung et al. | Longitudinal Magnetic Resonance Imaging with ROS‐Responsive Bilirubin Nanoparticles Enables Monitoring of Nonalcoholic Steatohepatitis Progression to Cirrhosis | |
| Sekas et al. | The evaluation of liver function after partial hepatectomy in the rat: serum changes. | |
| US20060193781A1 (en) | Magnetic resonance imaging of metal concentrations | |
| Samuelson et al. | Serum bile acids after a test meal in Crohn's disease | |
| JPH10509424A (ja) | 磁気共鳴イメージングで顕著な効果を示すキレート錯体 | |
| MXPA00001566A (en) | Liver function test | |
| KR20210014204A (ko) | 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물 | |
| Campbell et al. | Postprandial changes in serum concentrations of individual bile salts in normal subjects and patients with acute viral hepatitis | |
| Milkiewicz et al. | Plasma elimination of cholyl‐lysyl‐fluorescein (CLF): a pilot study in patients with liver cirrhosis | |
| Bloomer et al. | Hepatic clearance of unconjugated bilirubin in cholestatic liver diseases | |
| Alleman et al. | Familial porphyria cutanea tarda: the pattern of porphyrins formed from porphobilinogen by hemolysates. | |
| JP2001510569A (ja) | 血漿容積の測定 | |
| Stellaard et al. | Assessment of modes of action and efficacy of plasma cholesterol-lowering drugs: measurement of cholesterol absorption, cholesterol synthesis and bile acid synthesis and turnover using novel stable isotope techniques | |
| Gitnick | Assessment of liver function | |
| WO1997030734A1 (en) | Magnetic resonance blood pool agents | |
| Sawa et al. | The role of copper and zinc as pathogenic factors in liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150803 |